Here are the DEF 14A proxy statements from MIRA Pharmaceuticals, Inc. (MIRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MIRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MIRA filings page.
MIRA Pharmaceuticals, Inc. plans a virtual annual shareholders meeting on September 11, 2026, with holders of common stock at the July 21, 2026 record date (when 42,022,087 shares were outstanding) entitled to vote. Shareholders will vote on electing five directors, ratifying Salberg & Company, P.A. as independent auditor for 2026, and approving a possible adjournment to solicit additional proxies. The Board recommends voting FOR all three proposals.
The Board reports that four of five directors are independent under Nasdaq Listing Rules and oversees audit, compensation, and nominating/governance committees. In 2025, CEO Erez Aminov received total compensation of $5,304,174, including salary, cash bonuses tied to capital-raising and strategic goals, vested RSUs linked to market-cap milestones, and a significant stock option grant. As of the beneficial ownership date, Aminov beneficially owns 9,196,741 shares, or 19.34% of outstanding stock; all directors and officers as a group hold 19.89%. A related-party financing from the Bay Shore Trust provided up to $5,000,000 of credit, part of which converted into equity, along with a warrant for up to 1,000,000 shares at $5.00 per share, and the note has been repaid. The company also highlights its 2022 Omnibus Incentive Plan with millions of options and RSUs outstanding and a remaining share reserve for future awards.